Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies to Raise $6.6M in Direct Offering

NEW YORK — Australian diagnostics firm Genetic Technologies said on Thursday that it has signed definitive agreements to sell approximately $6.6 million of its American Depositary Shares (ADSs) to undisclosed institutional investors.

Through the registered direct offering, Genetic Technologies said it will sell 1.25 million ADSs, each representing 600 of its ordinary shares, at a price of $5.25 each. The offering is expected to close next week, with HC Wainwright acting as the exclusive placement agent.

Genetic Technologies said that it will use the proceeds of the offering to help launch new products in the US and Europe, to fund R&D and reimbursement studies for its polygenic risk tests, prepare a COVID-19 severity risk test, and to establish a germline genetic testing division. The firm will also use the proceeds for working capital and to fund potential acquisitions, among other things.

In late 2020, Genetic Technologies said that it been notified that it had regained compliance with the Nasdaq's minimum stockholders' equity requirement for continued listing of its ADSs after raising $16.4 million through equity offerings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.